Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | From the bench to bedside: AML treatment

Charles Craddock • 9 Dec 2017
ASH 2017
General Azacitidine

Understanding the biology of human disease is of the utmost importance to advancing treatment. We are now making excellent headway in the bench-to-bedside translation of knowledge in acute myeloid leukemia (AML), as discussed here by Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Prof. Craddock discusses these breakthroughs.

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals